BIGBEAR
PHARMACEUTICALS
Ibrutinib is a targeted therapy drug. Its main component acts precisely on Bruton's tyrosine kinase (BTK), which functions as a "switch controller" in B cells.
AuthenticGuaranteeFast DeliveryPrivacy NORTH CHICAGO, Ill., March 4, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Adm···【Read More】
Update: 27 Feb,2026Source: Haiou HealthViews: 69
NORTH CHICAGO, Ill., Jan. 19, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the U.S. Food and Dru···【Read More】
Update: 27 Feb,2026Source: Haiou HealthViews: 69
August 2, 2017 -- The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with ···【Read More】
Update: 27 Feb,2026Source: Haiou HealthViews: 69
HORSHAM, Pa., August 27, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (F···【Read More】
Update: 27 Feb,2026Source: Haiou HealthViews: 69
HORSHAM, PA, January 28, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Dru···【Read More】
Update: 27 Feb,2026Source: Haiou HealthViews: 69
About Chronic Graft-Versus-Host Disease (cGVHD)Chronic graft-versus-host disease is a life-threatening complication that can occur after a stem cell o···【Read More】
Update: 27 Feb,2026Source: Haiou HealthViews: 69
HORSHAM, PA. February 26, 2024 – Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced to···【Read More】
Update: 27 Feb,2026Source: Haiou HealthViews: 69
Copyright2024@ BIGBEAR All right reserved BIGBEAR
